Volume 95 Issue 11 | p. 15 | Concentrates
Issue Date: March 13, 2017

China’s BeiGene plans biologics plant

Department: Business
Keywords: biologics, oncology, BeiGene

Beijing-based oncology drug discovery firm BeiGene is joining with the government of Guangzhou in southern China to build a $330 million biologic drug facility in the Guangzhou Development District. The venture will also fund biologic drug R&D in China. Under the agreement, $30 million will come from BeiGene and $150 million from Guangzhou. The venture will borrow the rest. BeiGene says it needs large-scale manufacturing facilities to ensure growth.

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society